NextCure’s $5.5M equity falls short of Nasdaq minimum
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
NextCure, Inc. (NXTC) received notice of Nasdaq equity noncompliance on November 16, 2026. Its stockholders’ equity was $5.503 million, below Nasdaq’s $10.0 million minimum, based on the amount reported for the quarter ended September 30, 2026. Nasdaq also said the company did not meet alternative standards based on the market value of listed securities or total assets and revenue. NextCure has 45 calendar days, until January 4, 2027, to submit a plan to regain compliance.
The proposed merger with Avere Therapeutics is expected to close in mid-December 2026, subject to stockholder approval and other customary closing conditions. NextCure believes closing before the deadline would result in the company regaining compliance and may eliminate the need to submit a plan. If the merger is not completed before the Grace Period ends, NextCure intends to submit a plan. The company said there can be no assurance it will regain compliance or maintain compliance with other Nasdaq listing requirements.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Moderate pointStockholders’ equity was $5.503 million, below the $10.0 million Nasdaq minimum.
Filing Explained
The notice has not immediately changed trading or listing: NextCure’s common stock continues to be listed and traded on the Nasdaq Global Select Market, but remains subject to other Nasdaq listing requirements.
8-K Event Classification
Key Figures
Key Terms
Minimum Stockholders’ Equity Requirement regulatory
Grace Period regulatory
Nasdaq Listing Rule 5450(b)(1)(A) regulatory
alternative compliance standards regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Nasdaq notify NextCure (NXTC) of a listing deficiency?
When must NextCure (NXTC) submit a Nasdaq compliance plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.